CAS: 127-68-4; Sodium 3-Nitrobenzenesulphonate

相似化合物

79326-96-8 15959-31-6 6214-21-7

上下游产品

nitrobenzene2-Hydroxy-5-methylisophthalaldehyde 5-methoxy-[4,7]phenanthroline 8-hydroxyquinoline-5-carbaldehyde 3-chlorosalicylaldehyde

专利信息

专利号:US-6987186-B2
优先权日:2003-01-28
标 题 :Synthesis of small particle size quinacridone of beta crystal phase
发明人：COLE DAMIEN THURBER; JEGANATHAN SURULIAPPA GOWDER; HE YINGXIA
权利人:CIBA SC HOLDING AG
摘要:The present invention relates to a process for the synthesis of beta-quinacridone by oxidation in the presence of selected additives that promote the formation of the desired crystal phase and particle size.

专利号:US-5457203-A
优先权日:1993-09-15
标 题:Pigmentary synthesis of quinacridone solid solutions
发明人：HENDI SHIVAKUMAR B; JAFFE EDWARD E
权利人:CIBA GEIGY CORP
摘要:A general method for the direct preparation of pigmentary quinacridone solid solutions is disclosed. The disclosed process comprises oxidizing a mixture of dihydroquinacridones directly to a pigmentary quinacridone solid solution wherein the oxidation is carried out by heating a reaction mixture comprising the dihydroquinacridone mixture, an alkali metal hydroxide, a water miscible organic solvent, water and effective mounts of an oxidizing agent and a particle growth inhibitor. In addition, an analogous process useful for the direct pigmentary synthesis of α-quinacridone is disclosed. The pigments prepared by the disclosed processes do not require additional particle-size reducing after treatments in order to be useful as pigments.

专利号:US-4133828-A
优先权日:1975-08-28
标题:Manufacture of dimethylaminobenzenesulfonates
发明人：SCHEUERMANN HORST; HOCH HELMUT
权利人:BASF AG
摘要:Dimethylaminobenzenesulfonates are manufactured by reacting nitrobenzenesulfonates with formaldehyde and hydrogen in the presence of a hydrogenation catalyst containing a metal of atomic number from 24 to 29 and of phosphoric acid and water at a pH of from 2 to 3.5, at from 50 to 150° C, under a pressure of at least 40 bars, with a residence time of from 1 to 15 minutes. The products are starting materials for the synthesis of dyes, especially of rhodamine dyes, oxazine dyes and reactive dyes, and also of pharmaceuticals and pesticides.

专利号:US-RE45612-E
优先权日:2001-05-04
标 题 :Corrosion inhibitor composition applicable for aluminum and steel protection and procedure
发明人：SINKO JOHN
权利人:SINKO JOHN; MD FIFTH WARD PROPERTIES INC
摘要:A corrosion-inhibiting composition for application to a metal substrate, such as aluminum or steel, and in connection with a paint, and the synthesis of the composition. The active inhibitor constituent of the composition can be selected from the group consisting of 2,5-dimercapto-1,3,4 thiadiazole (DMTD), 2,4-dimercapto-s-triazolo-[4,3-b]-1,3-4-thiadiazole, trithiocyanuric acid (TMT), and derivatives of DMTD and TMT, including various N— or S— and N, N—, S— and N—,S-substituted derivatives of DMTD, including salts of DMTD of the general formula: M(DMTD) n , where n=1,2 or 3, and M is a metal cation and preferably M=Zn(II), Bi(III), Co(II), Ni(II), Cd(II), Pb(II), Ag(I), Sb(III), Cu(II), Li(I), Ca(II), Sr(II), Mg(II), La(III), Ce(III), Pr(III), Al(III) or Zr(IV). DMTD, TMT, and their derivatives may also be combined with phosphates, molybdates, borates, silicates, tungstates, phosphotungstates, phosphomolybdates, cyanamides, carbonates, SiO 2 and mixtures thereof.

专利号:US-2004229057-A1
优先权日:2003-01-28
标 题 :Synthesis of small particle size quinacridone of beta crystal phase

专利号:US-2016038528-A1
优先权日:2013-03-15
标 题:Rapidly Adaptable Nano Therapeutics for Treatment of Infectious Disease
发明人：MALONE BRETT; BRYSON JOSHUA
权利人:TECHULON INC
摘要:The invention relates to rapidly adaptable nanotherapeutics. The therapeutics are nucleic acid molecules, such as, RNA, DNA, or modified-DNA. The nucleic acid therapeutics are preferably administered as a nanoparticle composition, further containing one or more synthetic polymers. The therapeutics are rapidly adaptable because the identification and design of the polynucleotide sequence containing the therapeutic sequence is based upon rapid computer-implemented bioinformatics and nucleic acid synthesis protocols. The rapid adaptable protocols differ from traditional methods of antibiotic and antipathogenic drug development, which are slow and do not address drug resistance issues. Furthermore, the invention encompasses a facility with dedicated apparatus for practicing the invention in military theater or where emerging pathogenic threats are located. This facility may be mobile and transportable as a dedicated unit.